Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Honeywell International Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Honeywell International Inc trades at $222.65 (market cap $70.41B). The key difference: Honeywell International Inc is far larger — about 8.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Honeywell International Inc pays a 4.28% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HON | |
|---|---|---|
Market Cap | $8.02B | $70.41B |
Sector | Health | Industrials |
52-Week High | $339.75 | $248.04 |
52-Week Low | $241.71 | $188.14 |
Enterprise Value | $7.84B | $94.76B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Honeywell (HON) trades at $222.25, down 1.84% on the day, with a bearish technical signal. The company reported strong recent earnings beats but faces near-term uncertainty from its Aerospace and Quantinuum spinoffs. Key financials show solid profitability with a 10.89% net margin and 26.41% ROE, though revenue declined slightly in 2025. A recent 2:1 reverse stock split and updated 2026 guidance aim to streamline operations. Analyst consensus remains strongly bullish with a $368.55 price target, but technical indicators suggest caution.
The outlook for HON hinges on successful execution post-spinoff and margin improvement targets. Investment opportunity lies in its focused automation and industrial technology portfolio, attractive valuation (P/E 17.75), and strong analyst support. Key risks include near-term earnings volatility, competitive pressures, and macroeconomic headwinds impacting industrial demand. The stock's current bearish technical trend warrants monitoring for stabilization above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
